Fortescue share price tumbles 2.7% to A$21 as iron ore nerves return — what to watch next week
30 January 2026
1 min read

Fortescue share price tumbles 2.7% to A$21 as iron ore nerves return — what to watch next week

Sydney, Jan 30, 2026, 17:04 AEDT — After-hours

  • Fortescue fell 2.73% to A$21.00 on Friday, marking another volatile day in a jittery January.
  • Traders kept a close eye on iron ore cues and updates on China’s demand.
  • Fortescue’s half-year results are set for Feb. 25.

Fortescue Ltd shares dropped 2.73%, ending Friday at A$21.00—their lowest close in a week—as the iron ore miner followed a late-month retreat among bulk-commodity stocks. 1

This shift is significant since Fortescue’s profits hinge on iron ore prices and volumes. The market has flipped from celebrating “record shipments” to questioning China’s next move. China remains the biggest driver of seaborne iron ore demand, but its steel production has been slowing, despite imports holding firm last year. 2

Fortescue’s fate hinges on the benchmark prices it tracks. In its December-quarter report, the company revealed it secured 88% of the average Platts 62% CFR index price for hematite — the key seaborne iron ore benchmark delivered to northern China.

Benchmark 62% iron ore prices have stayed close to the mid-$100s per tonne this week, putting the onus on equities to drive market swings when sentiment changes. 3

Fortescue’s drop on Friday follows investor unease over rising costs flagged earlier this month. The miner posted December-quarter hematite unit cash costs (C1 — a standard cash cost metric) at $19.10 per wet metric tonne, a 5% increase from the previous quarter, though it left its fiscal 2026 shipment and cost forecasts untouched.

“Shipments hit record highs across our operations in the first half,” Metals and Operations CEO Dino Otranto said in the update.

Morningstar analyst Jon Mills noted this week that rising diesel prices and currency fluctuations drove costs higher. He added that “a stronger AUD/USD exchange rate could further affect unit cash costs in USD terms.” 4

But the risk remains. Should China’s steel production continue to slip while fresh supply comes online—like the Simandou project in Guinea that investors are watching—iron ore prices could tumble fast. Fortescue is typically hit harder than its more diversified rivals. 2

Traders are gearing up to monitor the next move in iron ore futures, alongside any new developments in China’s steel and construction sectors that could steer bulk commodity trends heading into February. 2

Fortescue’s upcoming FY26 half-year results, due Feb. 25, will be a key moment. Investors will zero in on cost control, realised prices, and any changes to capital spending. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
PLS Group share price slides on cost jump, Ngungaju restart talk jars investors
Previous Story

PLS Group share price slides on cost jump, Ngungaju restart talk jars investors

NAB share price rises as rate-hike bets build — what investors watch next week
Next Story

NAB share price rises as rate-hike bets build — what investors watch next week

Go toTop